Page 12 - 8_04

Access to medicines
Editorial. US presidential candidates' proposals to
reduce drug prices. The Lancet 2016; 388: 855-6.
12. Huang WS, Metcalf CA, Sundaramoorthi R, Wang Y,
et al. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-
yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-
yl)methyl]-3-(trifluoromethyl)phenyl}benzamide
(AP24534), a potent, orally active pan-inhibitor of
breakpoint cluster region-abelson (BCR-ABL) kinase
including the T315I gatekeeper mutant. J Med Chem
2010; 53: 4701-19.
13. Orden HAP/1169/2016 de 14 de Julio, BOE Núm. 171,
16 de Julio de 2016, Sección I, Pág. 50232-6.
14. Novak SP, Håkansson A, Martinez-Raga J, Reimer
J, Krotki K, Varughese S. Nonmedical use of
prescription drugs in the European Union. BMC
Psychiatry 2016; DOI: 10.1186/s12888-016-0909-3.
15. Mestre-Ferrandiz J, Sussex J, Towse A. The R&D Cost
of a New Medicine. OHE (Office of Health
Economics) Research paper, London (2012).
16. a) Ferrario A, Kanavos P. Managed entry agreements
for pharmaceuticals: the European experience. Final
report, London School of Economics and Political
Science, 2013. EMINEet, Brussels, Belgium. b)
Garrison LP, Toese A, Briggs A, et al. Informe del
Grupo de trabajo de ISPOR sobre Buenas Prácticas
para los Acuerdos de Riesgo Compartido basado en el
Desempeño. Value in Health, 2013; 16: 703-19. c)
LAA, Bernardini C, Siviero PD, Montilla S, Pani L.
Managed entry agreements. Orphanet J Rare Dis.
2014; doi: 10.1186/1750-1172-9-S1-O27.
17. a) Goluboff ET, Olsson CA. Urologists on a tightrope:
coping with a changing economy. J Urol. 1994; 151:
1-4. b) Albertsen PC, Pellissier JM, Lowe FC, et al.
Economic analysis of finasteride: A model-based
approach using data from the Proscar® long-term
efficsacy and safety study. Clin Therap 1999; 21:
1006-24.
18. a) Guillemont J1, Meyer C, Poncelet A, Bourdrez X,
Andries K. Diarylquinolines, synthesis pathways and
quantitative structure-activity relationship studies
leading to the discovery of TMC207. Future Med
Chem 2011; 3: 1345-60.b) Mahajan R. Bedaquiline:
First FDA-approved tuberculosis drug in 40 years. Int
J Appl Basic Med Res 2013; 3: 1-2.
19. Avorn J. Approval of a tuberculosis drug based on a
paradoxical surrogate measure. JAMA 2013; 309:
1349-50.
20. Ver Informe de Posicionamiento Terapéutico en :
https://www.aemps.gob.es/medicamentosUsoHumano
/informesPublicos/docs/IPT-bedaquilina-Sirturo-
tuberculosis-pulmonar.pdf.
21. a) Hill A, Khoo S, Fortunak J, Simmons B, Ford N.
Minimum Costs for Producing Hepatitis C Direct-
Acting Antivirals for Use in Large-Scale Treatment
Access Programs in Developing Countries. Clinical
Infectious Diseases 2014; doi:10.1093/cid/ciu012. b)
Avendaño C. Noticias científicas: Análisis. United
@Real Academia Nacional de Farmacia. Spain
States to approve potent oral drugs for hepatitis C.
Improved treatments offer hope for eradication of
viral liver infection. An Real Acad Farm 2014; 80:
242-9.
22. Redacción Médica. 6 de octubre de 2016.
23. Editorial. Hepatitis C: cost of lost opportunities. The
Lancet 2015; 386:1917.
24. Alwan A, editor. Global status report on
noncommunicable diseases 2010. Geneva: World
Health Organization; 2011.
25. Razmaria A. Surgeon, Scientist, and Entrepreneur: One
Man’s Fight Against Cancer. JAMA 2016; 316: 1345-
7.
26. a) Briger I, Dubemet C, Couvreur P. Nanoparticles in
cancer therapy and diagnosis. Adv Drug Deliv Rev
2002; 54: 631-51. b) Moghimi SM, Hunter AC,
Murray JC. Nanomedicine: current status and future
prospects. FASEB J 2005; 19: 311-30.
27. a) Paramore A, Frantz S. Bortezomib. Nature Rev
Drug Discov 2003; 2: 611-2. b) Kane RC, Bross PF,
Farrell AT, Pazdur R. Velcade: U.S. FDA approval for
the treatment of multiple myeloma progressing on
prior therapy. Oncologist. 2003; 8: 508-13. c) Moreau
P, Richardson PG, Cavo M, Orlowski RZ, San Miguel
JF, Palumbo A, Harousseau J-L. Proteasome
inhibitors in multiple myeloma: 10 years later. Blood
2012; 120: 947-59.
28. Kisselev AF, van der Linden WA, Overkleeft HS.
Proteasome Inhibitors: An Expanding Army Attacking
a Unique Target. Chem Biol 2012; 19: 99-115.
29. Maier SK, Hammond JM. Role of lenalidomide in the
treatment of multiple myeloma and myelodysplastic
síndrome. Ann Pharmacother 2006; 40: 286-9.
30. Huber ML, Haynes L, Parker C, Iversen P.
Interdisciplinary critique of sipuleucel-T as
immunotherapy in castration-resistant prostate cáncer.
J Natl Cancer Inst 2012; 104: 273-9.
31. Avendaño C, Menéndez JC. Medicinal Chemistry of
anti-cancer drugs. Second Edition, Elsevier, 2015,
Chapter 12, pag. 576.
32. European Medicines Agency. Document reference
EMA/837805/2011. Questions and answers on
biosimilar medicines (similar biological medicinal
products). London: EMA 2012.
33. Mestre-Ferrandiz J, Towse A, Berdud M. Biosimilars:
How Can Payers Get Long-Term Savings?,
PharmacoEconomics 2016; 34: 609-16.
34. Grabowski HG, Guha R, Salgado M. Biosimilar
competition: lessons from Europe. Nat Rev Drug
Discov. 2014; 13: 99-100.
371